Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 20,640 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood Specimen Clear all
Active, not recruiting Phase 2Phase 3 Interventional

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04442022
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Interventions
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
8
States / cities
Chandler, Arizona • Tucson, Arizona • Cerritos, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 24, 2026, 6:37 PM EDT
Completed No phase listed Observational

Accuracy of Pulse CO-Oximetry Technology in Characterizing Noninvasive SpHb

NCT01997502
View directory record Official record
Conditions
Surgery, Hemoglobin
Interventions
Pulse CO-Oximetry Technology, Blood draw
Device · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 24, 2026, 6:37 PM EDT
Withdrawn Not applicable Interventional

The Effect of Atrial Fibrillation Hemodynamics on Regulation of Cerebral Blood Flow

NCT00745602
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
non-invasive testing
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 24, 2026, 6:37 PM EDT
Completed Phase 1 Interventional

Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors

NCT01055795
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Bevacizumab, Everolimus and LBH589
Drug
Lead sponsor
Herbert Hurwitz
Other
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 24, 2012 · Synced Oct 24, 2026, 6:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

NCT02059239
View directory record Official record
Conditions
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Bendamustine, Carmustine, Etoposide, Melphalan, Cytarabine, Alemtuzumab, Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Rituximab
Drug · Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 24, 2026, 6:37 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT05355701
View directory record Official record
Conditions
Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)
Interventions
PF-07799933, binimetinib, cetuximab, midazolam, fluorouracil, leucovorin, oxaliplatin
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
31
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 24, 2026, 6:37 PM EDT
Recruiting No phase listed Observational

Longitudinal Study of Intra-Uterine Growth Restriction

NCT02382601
View directory record Official record
Conditions
IUGR, Pregnancy
Interventions
Ultrasound, MRI, Blood collection, Neurological Function Assessment, Placental Analysis, Measurement of body fat, Pediatric heart ultrasound
Radiation · Procedure · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 24, 2026, 6:37 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

NCT03851081
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5 Percent or More of Peripheral Blood White Cells, CD22 Positive, Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells, Lymphoblasts 20 Percent or More of Peripheral Blood White Cells, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Interventions
Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 24, 2026, 6:37 PM EDT
Completed Phase 3 Interventional Results available

Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

NCT00082381
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide (AC2993), Insulin glargine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
21
States / cities
San Diego, California • San Mateo, California • Fort Myers, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 24, 2026, 6:37 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients

NCT00543569
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Alefacept, tacrolimus, basiliximab, mycophenolate mofetil, Corticosteroids
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
38
States / cities
Loma Linda, California • Los Angeles, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 24, 2026, 6:37 PM EDT
Recruiting No phase listed Observational

Longitudinal Advanced Prostate Cancer Cohort (LAPCC)

NCT06067295
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 24, 2026, 6:37 PM EDT
Completed Not applicable Interventional Results available

AccuCath™ Intravenous (IV) Device Used by Vascular Access Team (VAT)

NCT01937195
View directory record Official record
Conditions
Vascular Access Complication
Interventions
AccuCath Intravenous Catheter System
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years to 89 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lewisburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 24, 2026, 6:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients

NCT01419275
View directory record Official record
Conditions
Cerebrovascular Accident, Moyamoya Disease
Interventions
Xenon contrast agent, Magnetic Resonance Imaging
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 24, 2026, 6:37 PM EDT
Completed Not applicable Interventional Results available

Telehealth-enhanced Hybrid Cardiac Rehabilitation Among Acute Coronary Syndrome Survivors

NCT05328375
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction
Interventions
Telehealth-enhanced Hybrid CR, Traditional CR
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 24, 2026, 6:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)

NCT01736475
View directory record Official record
Conditions
Hemophilia A
Interventions
Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Aurora, Colorado • Gainesville, Florida • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 24, 2026, 6:37 PM EDT
Not yet recruiting Not applicable Interventional

Clinical Evaluation of an Alarm Activated Detection System to Enable Early Intervention of Emerging Respiratory Decline With the Linshom Medical Continuous Predictive Respiratory Sensor (CPRS)

NCT07793981
View directory record Official record
Conditions
Post Surgical Respiratory Failure, Respiratory Complication, Opioid Induced Respiratory Depression, Respiratory Arrest
Interventions
Linshom Continuous Predictive Respiratory Monitoring
Device
Lead sponsor
Linshom Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 24, 2026, 6:37 PM EDT
Completed No phase listed Observational

Use of the Quantra QPlus Sytem in Cardiac Surgery

NCT05501730
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Quantra QPlus System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Prescott, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 24, 2026, 6:37 PM EDT
Completed Phase 1Phase 2 Interventional

Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation

NCT00029328
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans, Pneumonia
Interventions
etanercept
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
12 Months and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 24, 2026, 6:37 PM EDT
Withdrawn No phase listed Observational

Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy

NCT02414100
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
Laboratory Biomarker Analysis, Cytology Specimen Collection Procedure
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 24, 2026, 6:37 PM EDT
Completed Phase 2 Interventional Results available

Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response

NCT00841100
View directory record Official record
Conditions
Phenylketonuria
Interventions
Kuvan, Diet
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
4 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 24, 2026, 6:37 PM EDT
Completed Phase 1 Interventional

Photobiomodulation to Alter Cerebral Blood Flow and to Affect the Emotional Status of Patients With Major Depression

NCT00961454
View directory record Official record
Conditions
Major Depression, Anxiety Disorder, Post-Traumatic Stress Disorder, Substance Abuse Disorder
Interventions
Photobiomodulation with a super-luminous light emitting diode
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2009 · Synced Oct 24, 2026, 6:37 PM EDT
Completed Not applicable Interventional Results available

Glucose Measurement Using Microneedle Patches

NCT02682056
View directory record Official record
Conditions
Diabetes
Interventions
Microneedle patch, Intravenous (IV) catheter, Lancet
Device
Lead sponsor
Emory University
Other
Eligibility
7 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 24, 2026, 6:37 PM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

NCT00904722
View directory record Official record
Conditions
Lymphoma
Interventions
CT-011, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 24, 2026, 6:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

NCT07293351
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma (RCC)
Interventions
Pumitamig, Ipilimumab, Cabozantinib, Casdatifan
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
17
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 6:37 PM EDT